Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib

SHENG-KAI LIANGWei, Pin-FeiPin-FeiWeiMIN-SHU HSIEHWu, Chia-LingChia-LingWuJIN-YUAN SHIH2024-04-262024-04-262024-032312-0541https://scholars.lib.ntu.edu.tw/handle/123456789/642070Afatinib, an irreversible ErbB family inhibitor, is widely used as first-line treatment in advanced lung adenocarcinoma patients harbouring mutant epidermal growth factor receptor (EGFR). With the advancements in next-generation sequencing (NGS), comprehensive research into the clinical impact of co-occurring genetic mutations and the molecular mechanisms of acquired resistance is required for afatinib users.en[SDGs]SDG3Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinibjournal article10.1183/23120541.00676-2023385007952-s2.0-85189294503https://api.elsevier.com/content/abstract/scopus_id/85189294503